Intravenous or inhaled salbutamol in severe acute asthma?

STEPHEN WILLIAMS AND ANTHONY SEATON

From the Asthma Research Unit, Sully Hospital, Penarth, South Glamorgan CF6 2YA, UK

Williams, S., and Seaton, A. (1977). Thorax, 32, 555–558. Intravenous or inhaled salbutamol in severe acute asthma? Ten patients with life-threatening attacks of asthma (‘status asthmaticus’) were treated with salbutamol inhaled by intermittent positive pressure breathing, and their response in terms of rise in peak flow rate was measured. They were then given intravenous salbutamol and any further increment in peak flow was measured. Hydrocortisone treatment was started simultaneously and the responses to salbutamol were re-measured on each of the next three days. Only two patients initially responded to the aerosol, whereas all save one responded to the intravenous drug. The two who responded initially to the aerosol were the two who were able to produce sputum at the time of admission. All patients subsequently responded to the aerosol, and the onset of this response correlated closely with the beginning of sputum production. Sympathomimetics should be given parenterally to patients in severe asthma if the response to inhaled drug is reduced or absent.

Corticosteroids may take several hours or even days before producing a measurable improvement in ventilatory function in patients with severe asthma (Collins et al., 1975).

Bronchodilators are usually necessary during this period and β-stimulant drugs are commonly used though it has been reported that the β effects of adrenergic stimulation are often diminished in severe asthma (Cookson and Read, 1963; Ellul-Micallef and Fenech, 1975). The β-2 stimulant drug, salbutamol, when given by intermittent positive pressure nebulisation (IPPB), has been shown to produce significant bronchodilatation in chronic asthmatics (Choo-Kang et al., 1970) while it is also effective given intravenously in severe acute asthma (Fitchett et al., 1975; Williams et al., 1975). The purposes of the present study were to determine the best mode of administration of salbutamol at various times during a severe asthmatic attack and to investigate the possibility of β-receptor blockade in these patients.

Methods

The study protocol was approved by the area ethics committee. Ten patients gave informed consent. All were admitted with severe asthma satisfying the criteria of a pulse >120 per minute, peak flow rate <25% predicted, and a Pao₂ <70 mmHg (9.3 kPa). Eight had been using sympathomimetic inhalers before the attack (Table 1). None had any therapy in the two hours before entry to the trial.

The peak flow rate (PFR—best of three attempts) was measured on admission by Wright peak flow meter. An aerosol of 5 mg salbutamol was then given by positive pressure nebulisation (Ohio hand-e-vent) supervised in all cases by one of us (SW). PFR was then measured at 5-minute intervals until a maximum was reached. At this time salbutamol (200 µg) was injected intravenously over 10 minutes. PFR continued to be recorded every 5 minutes until a plateau occurred. The whole procedure was repeated at 24-hour intervals for three days.

Each patient was also treated with intravenous hydrocortisone (1 g 6-hourly initially), oral prednisone, oxygen, and antibiotics, these being started at the time of admission. Each patient was asked at the time of the daily salbutamol tests whether he had produced any sputum in the preceding 24 hours. The first 24-hour period in which he did this was recorded (eg, on admission or on days 1, 2 or 3) (Table 1).

Results

Analysis of results was by Student’s t test for
paired samples. Table 2 shows that the mean initial PFR on the day of admission was 91 l/min and after inhalation of salbutamol there was no significant increase. In individual patients only two of the 10 showed a rise of greater than 10% in PFR after the inhalation. These two patients were the only ones who were producing sputum at the time of admission.

After the intravenous salbutamol, the mean PFR of the 10 patients showed a significant rise to 145 l/min. Only one of the 10 patients failed to show a rise after intravenous salbutamol and those two who had responded to aerosol also showed an additional response to the intravenous drug. This rise after intravenous drug was statistically significant (p<0.01).

Each day there was an increase in the initial mean PFR of the patients in keeping with their expected responses to high-dose steroids. Along with this initial rise there was an increased response to inhaled salbutamol and a progressively smaller increment after intravenous salbutamol. On day three there was a maximal response to the aerosol and no significant further increase after the intravenous drug (Table 2). This pattern of response occurred in all 10 patients.

The response to aerosol salbutamol related closely to sputum production. The two who responded initially were the only ones who were producing sputum. Table 3 shows the mean PFR before and on the day of sputum production in the other eight patients. There was a significant response to intravenous salbutamol before sputum production and to aerosol after sputum production. The baseline PFR, before drug administration, also increased at the time of sputum production, as seen in Table 3.

The pattern of response did not relate to previous duration of asthma, duration of the attack, or administration of oral steroids before admission. Increased skill in the use of the IPPB device did not seem to play a part as its use was supervised by one of us in all patients and there was no difference in response between those who had previously used the device and those who had not.

### Table 1 Clinical details of patients studied

<table>
<thead>
<tr>
<th>Case</th>
<th>Sex</th>
<th>Age (yr)</th>
<th>Duration of previous asthma (yr)</th>
<th>Duration of episode studied</th>
<th>Maintenance therapy</th>
<th>Day of sputum production</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>M</td>
<td>41</td>
<td>25</td>
<td>3 weeks</td>
<td>Prednisone</td>
<td>On admission</td>
</tr>
<tr>
<td>2</td>
<td>F</td>
<td>22</td>
<td>12</td>
<td>2 days</td>
<td></td>
<td>1</td>
</tr>
<tr>
<td>3</td>
<td>M</td>
<td>22</td>
<td>10</td>
<td>2 days</td>
<td>Medihaler</td>
<td>1</td>
</tr>
<tr>
<td>4</td>
<td>M</td>
<td>37</td>
<td>20</td>
<td>14 hours</td>
<td></td>
<td>1</td>
</tr>
<tr>
<td>5</td>
<td>F</td>
<td>19</td>
<td>10</td>
<td>2 days</td>
<td>Medihaler</td>
<td>3</td>
</tr>
<tr>
<td>6</td>
<td>M</td>
<td>53</td>
<td>2</td>
<td>1 week</td>
<td></td>
<td>2</td>
</tr>
<tr>
<td>7</td>
<td>F</td>
<td>51</td>
<td>10</td>
<td>5 days</td>
<td></td>
<td>3</td>
</tr>
<tr>
<td>8</td>
<td>F</td>
<td>49</td>
<td>10</td>
<td>3 days</td>
<td>Medihaler</td>
<td>1</td>
</tr>
<tr>
<td>9</td>
<td>M</td>
<td>54</td>
<td>25</td>
<td>1 week</td>
<td>Prednisone</td>
<td>On admission</td>
</tr>
<tr>
<td>10</td>
<td>M</td>
<td>54</td>
<td>0</td>
<td>2 days</td>
<td>Medihaler</td>
<td>1</td>
</tr>
</tbody>
</table>

### Table 2 Peak flow rate (PFR) before drug administration and rise after inhaled and intravenous salbutamol: means, standard deviation in parentheses

<table>
<thead>
<tr>
<th>Initial PFR (l/min)</th>
<th>Differences between initial PFR and PFR after inhaled salbutamol (l/min)</th>
<th>Differences between initial PFR and PFR after intravenous salbutamol (l/min)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0</td>
<td>5 min</td>
</tr>
<tr>
<td>On admission</td>
<td>91 (27)</td>
<td>8.5</td>
</tr>
<tr>
<td>Day 1</td>
<td>140 (24)</td>
<td>17</td>
</tr>
<tr>
<td>Day 2</td>
<td>176 (19)</td>
<td>31</td>
</tr>
<tr>
<td>Day 3</td>
<td>195 (20)</td>
<td>46</td>
</tr>
</tbody>
</table>

We have shown that severe asthma may prove fatal in a very short space of time (MacDonald...
et al., 1976a; Macdonald et al., 1976b). It is important, therefore, that the initial treatment should be the most effective available. Hume and Gandevia (1957) were probably the first to demonstrate that the response to inhaled bronchodilators in asthma varied in an individual in relation to the severity of his airways obstruction. In their subjects, severe obstruction was associated with little response. There was then an increasing response as the obstruction was relieved and subsequently a smaller response again as the subject’s maximal state of bronchodilatation was achieved. Other workers, notably Rebuff and Read (1971), have confirmed that in severe attacks of asthma the patients are frequently in a non-responsive phase, and the latter authors used this as an index of severity of the attack.

The reasons for this failure to respond to inhaled bronchodilators have not hitherto been clarified. In severe asthma, not only is bronchial smooth muscle constriction present, but also mucosal thickening, bronchial wall oedema, and mucus plugging play a major part in causing airways obstruction (Williams and Leopold, 1959). This mechanism of bronchial narrowing would not be expected to respond to bronchodilators and moreover might be expected to prevent the access of inhaled drugs.

In addition it has been suggested that severe asthmatics may develop partial $\beta$-receptor blockade (Cookson and Reed, 1963) and that this potentially dangerous effect may be relieved by corticosteroids (Rebuff and Reed, 1971; Shenfield et al., 1975). Studies of this effect have generally relied upon failure of $\beta$-stimulant drugs given by aerosol to produce bronchodilatation.

In a previous study (Williams et al., 1975), we have shown that intravenous salbutamol is effective in severe acute asthma. We have now shown that inhaled salbutamol, like isoprenaline, is not normally effective in the same clinical situation until the patient begins to cough up the mucus that has been plugging the bronchi. That this lack of efficacy is not due to $\beta$-blockade has been demonstrated by the significant effect of intravenous salbutamol at a time when the aerosol produces no response. Only one of our patients failed initially to respond to both aerosol and intravenous salbutamol. In his case $\beta$-blockade is a possibility, but an alternative and equally likely reason is that his airways were predominantly obstructed by mucus plugging and that smooth muscle constriction was initially playing only a minor role. This patient had used no bronchodilators before his admission in this attack. Clearly, the possibility of $\beta$-blockade as an important factor in severe asthma is hard to prove, but from our studies it is plain that it cannot be assumed from a failure to respond to bronchodilators given by aerosol alone. Moreover, so-called potentiation of bronchodilators by steroids (Shenfield et al., 1975) may be explained on the basis of improving access of the bronchodilators to the airways as well as by biochemical mechanisms. In our patients there was, as expected, a rise in the baseline peak flow each day and this was undoubtedly the effect of corticosteroid treatment. Nevertheless, we were able to achieve a rise in peak flow from 91 to 145 l/min after intravenous salbutamol on the first day—a percentage change comparing favourably with that from 195 to 259 l/min after inhaled salbutamol after 36 hours’ high-dose corticosteroids. It seems likely that the effect of the steroids in these patients was largely to improve the accessibility of the bronchi to the inhaled drug by reducing the inflammatory reaction within them.

The practical message of our study is that the management of severe acute asthma requires administration of bronchodilators by the most effective route while waiting for corticosteroids to work. While sympathomimetics by IPPB may be effective in a number of patients, in those as severely ill as the ones we studied intravenous administration is the route of choice. When the patient begins to respond to the steroid therapy and, in particular, when he starts to produce sputum, IPPB becomes as effective as intravenous therapy.

References


Requests for reprints to: Dr. A. Seaton, Sully Hospital, Penarth, South Glamorgan CF6 2YA, UK.
Intravenous or inhaled salbutamol in severe acute asthma?
S Williams and A Seaton

*Thorax* 1977 32: 555-558
doi: 10.1136/thx.32.5.555

Updated information and services can be found at: [http://thorax.bmj.com/content/32/5/555](http://thorax.bmj.com/content/32/5/555)

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to: [http://group.bmj.com/group/rights-licensing/permissions](http://group.bmj.com/group/rights-licensing/permissions)

To order reprints go to: [http://journals.bmj.com/cgi/reprintform](http://journals.bmj.com/cgi/reprintform)

To subscribe to BMJ go to: [http://group.bmj.com/subscribe/](http://group.bmj.com/subscribe/)